US20060142228A1 - Methods and compositions concerning siRNA's as mediators of RNA interference - Google Patents

Methods and compositions concerning siRNA's as mediators of RNA interference Download PDF

Info

Publication number
US20060142228A1
US20060142228A1 US11/020,560 US2056004A US2006142228A1 US 20060142228 A1 US20060142228 A1 US 20060142228A1 US 2056004 A US2056004 A US 2056004A US 2006142228 A1 US2006142228 A1 US 2006142228A1
Authority
US
United States
Prior art keywords
seq
rna
sirna
pat
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/020,560
Other languages
English (en)
Inventor
Lance Ford
Joseph Krebs
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Applied Biosystems LLC
Original Assignee
Ambion Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ambion Inc filed Critical Ambion Inc
Priority to US11/020,560 priority Critical patent/US20060142228A1/en
Assigned to AMBION, INC. reassignment AMBION, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: FORD, LANCE P., KREBS, JOSEPH
Priority to EP05857194A priority patent/EP1830866A2/fr
Priority to PCT/US2005/046779 priority patent/WO2006078414A2/fr
Publication of US20060142228A1 publication Critical patent/US20060142228A1/en
Assigned to APPLERA CORPORATION reassignment APPLERA CORPORATION REDACED AGREEMENT AND PLAN OF MERGER DOCUMENT Assignors: AMBION, INC.
Assigned to BANK OF AMERICA, N.A, AS COLLATERAL AGENT reassignment BANK OF AMERICA, N.A, AS COLLATERAL AGENT SECURITY AGREEMENT Assignors: APPLIED BIOSYSTEMS, LLC
Priority to US12/484,948 priority patent/US8058255B2/en
Assigned to APPLIED BIOSYSTEMS, LLC reassignment APPLIED BIOSYSTEMS, LLC MERGER (SEE DOCUMENT FOR DETAILS). Assignors: APPLIED BIOSYSTEMS INC.
Assigned to APPLIED BIOSYSTEMS INC. reassignment APPLIED BIOSYSTEMS INC. CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: APPLERA CORPORATION
Assigned to APPLIED BIOSYSTEMS, INC. reassignment APPLIED BIOSYSTEMS, INC. LIEN RELEASE Assignors: BANK OF AMERICA, N.A.
Assigned to APPLIED BIOSYSTEMS, LLC reassignment APPLIED BIOSYSTEMS, LLC CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY NAME PREVIOUSLY RECORDED AT REEL: 030182 FRAME: 00677. ASSIGNOR(S) HEREBY CONFIRMS THE RELEASE OF SECURITY INTEREST. Assignors: BANK OF AMERICA, N.A.
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y102/00—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2)
    • C12Y102/01—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2) with NAD+ or NADP+ as acceptor (1.2.1)
    • C12Y102/01012—Glyceraldehyde-3-phosphate dehydrogenase (phosphorylating) (1.2.1.12)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y502/00—Cis-trans-isomerases (5.2)
    • C12Y502/01—Cis-trans-Isomerases (5.2.1)
    • C12Y502/01008—Peptidylprolyl isomerase (5.2.1.8), i.e. cyclophilin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/30—Production chemically synthesised
US11/020,560 2004-12-23 2004-12-23 Methods and compositions concerning siRNA's as mediators of RNA interference Abandoned US20060142228A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US11/020,560 US20060142228A1 (en) 2004-12-23 2004-12-23 Methods and compositions concerning siRNA's as mediators of RNA interference
EP05857194A EP1830866A2 (fr) 2004-12-23 2005-12-21 Methodes et compositions dans lesquelles sont utilises des siarn comme mediateurs de l'interference arn
PCT/US2005/046779 WO2006078414A2 (fr) 2004-12-23 2005-12-21 Methodes et compositions dans lesquelles sont utilises des siarn comme mediateurs de l'interference arn
US12/484,948 US8058255B2 (en) 2004-12-23 2009-06-15 Methods and compositions concerning siRNA's as mediators of RNA interference

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/020,560 US20060142228A1 (en) 2004-12-23 2004-12-23 Methods and compositions concerning siRNA's as mediators of RNA interference

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/484,948 Continuation US8058255B2 (en) 2004-12-23 2009-06-15 Methods and compositions concerning siRNA's as mediators of RNA interference

Publications (1)

Publication Number Publication Date
US20060142228A1 true US20060142228A1 (en) 2006-06-29

Family

ID=36612533

Family Applications (2)

Application Number Title Priority Date Filing Date
US11/020,560 Abandoned US20060142228A1 (en) 2004-12-23 2004-12-23 Methods and compositions concerning siRNA's as mediators of RNA interference
US12/484,948 Active US8058255B2 (en) 2004-12-23 2009-06-15 Methods and compositions concerning siRNA's as mediators of RNA interference

Family Applications After (1)

Application Number Title Priority Date Filing Date
US12/484,948 Active US8058255B2 (en) 2004-12-23 2009-06-15 Methods and compositions concerning siRNA's as mediators of RNA interference

Country Status (3)

Country Link
US (2) US20060142228A1 (fr)
EP (1) EP1830866A2 (fr)
WO (1) WO2006078414A2 (fr)

Cited By (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030166282A1 (en) * 2002-02-01 2003-09-04 David Brown High potency siRNAS for reducing the expression of target genes
US20040033602A1 (en) * 2002-06-12 2004-02-19 Ambion, Inc. Methods and compositions relating to polypeptides with RNase III domains that mediate RNA interference
US20040248094A1 (en) * 2002-06-12 2004-12-09 Ford Lance P. Methods and compositions relating to labeled RNA molecules that reduce gene expression
WO2009024834A2 (fr) * 2006-12-05 2009-02-26 Rosetta Genomics Ltd Acides nucléiques impliques dans les infections virales
WO2009029688A3 (fr) * 2007-08-27 2009-07-02 Boston Biomedical Inc Compositions d'arn interférent asymétrique et leurs utilisations
US20100018849A1 (en) * 2008-07-25 2010-01-28 Air Products And Chemicals, Inc. Removal of Trace Arsenic Impurities from Triethylphosphate (TEPO)
US20100075423A1 (en) * 2002-06-12 2010-03-25 Life Technologies Corporation Methods and compositions relating to polypeptides with rnase iii domains that mediate rna interference
US20100112686A1 (en) * 2008-10-15 2010-05-06 Qing Ge Short hairpin rnas for inhibition of gene expression
US20100159591A1 (en) * 2004-12-23 2010-06-24 Life Technologies Corporation METHODS AND COMPOSITIONS CONCERNING siRNA'S AS MEDIATORS OF RNA INTERFERENCE
US20100197772A1 (en) * 2007-07-18 2010-08-05 Andrea Califano Tissue-Specific MicroRNAs and Compositions and Uses Thereof
EP2222848A2 (fr) * 2007-12-18 2010-09-01 Lee, Dong Ki Nouvelle structure de petit arn interférent permettant d'atténuer les effets hors cible et d'alléger la saturation de mécanisme d'arn interférent, et utilisation
US20110237648A1 (en) * 2008-09-22 2011-09-29 Rxi Pharmaceuticals Corporation Rna interference in skin indications
US8426380B2 (en) 2004-09-10 2013-04-23 Somagenics, Inc. Inhibition of viral gene expression using small interfering RNA
US8815821B2 (en) 2002-02-01 2014-08-26 Life Technologies Corporation Double-stranded oligonucleotides
US8871730B2 (en) 2009-07-13 2014-10-28 Somagenics Inc. Chemical modification of short small hairpin RNAs for inhibition of gene expression
US9080171B2 (en) 2010-03-24 2015-07-14 RXi Parmaceuticals Corporation Reduced size self-delivering RNAi compounds
US9095504B2 (en) 2010-03-24 2015-08-04 Rxi Pharmaceuticals Corporation RNA interference in ocular indications
US9340786B2 (en) 2010-03-24 2016-05-17 Rxi Pharmaceuticals Corporation RNA interference in dermal and fibrotic indications
US9493774B2 (en) 2009-01-05 2016-11-15 Rxi Pharmaceuticals Corporation Inhibition of PCSK9 through RNAi
US9745574B2 (en) 2009-02-04 2017-08-29 Rxi Pharmaceuticals Corporation RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
US9777275B2 (en) 2002-02-01 2017-10-03 Life Technologies Corporation Oligonucleotide compositions with enhanced efficiency
US10125362B2 (en) 2012-05-22 2018-11-13 Olix Pharmaceuticals, Inc. RNA-interference-inducing nucleic acid molecule able to penetrate into cells, and use therefor
US10214744B2 (en) 2010-10-22 2019-02-26 Sungkyunkwan University Foundation For Corporate Collaboration Nucleic acid molecules inducing RNA interference, and uses thereof
US10519449B2 (en) 2016-02-02 2019-12-31 Olix Pharmaceuticals, Inc. Treatment of angiogenesis-associated diseases using RNA complexes that target ANGPT2 and PDGFB
US10590423B2 (en) 2015-11-16 2020-03-17 Olix Pharmaceuticals, Inc. Treatment of age-related macular degeneration using RNA complexes that target MyD88 or TLR3
US10808247B2 (en) 2015-07-06 2020-10-20 Phio Pharmaceuticals Corp. Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
US10829761B2 (en) 2016-04-11 2020-11-10 Olix Pharmaceuticals, Inc. Treatment of idiopathic pulmonary fibrosis using RNA complexes that target connective tissue growth factor
US10900039B2 (en) 2014-09-05 2021-01-26 Phio Pharmaceuticals Corp. Methods for treating aging and skin disorders using nucleic acids targeting Tyr or MMP1
US10934550B2 (en) 2013-12-02 2021-03-02 Phio Pharmaceuticals Corp. Immunotherapy of cancer
US10947541B2 (en) 2016-02-02 2021-03-16 Olix Pharmaceuticals, Inc. Treatment of atopic dermatitis and asthma using RNA complexes that target IL4Rα, TRPA1, or F2RL1
US11001845B2 (en) 2015-07-06 2021-05-11 Phio Pharmaceuticals Corp. Nucleic acid molecules targeting superoxide dismutase 1 (SOD1)
US11021707B2 (en) 2015-10-19 2021-06-01 Phio Pharmaceuticals Corp. Reduced size self-delivering nucleic acid compounds targeting long non-coding RNA
US11040057B2 (en) 2016-06-29 2021-06-22 Olix Pharmaceuticals, Inc. Pharmaceutical compositions and methods for potentiating gene silencing
US11279934B2 (en) 2014-04-28 2022-03-22 Phio Pharmaceuticals Corp. Methods for treating cancer using nucleic acids targeting MDM2 or MYCN
US11591600B2 (en) 2017-02-10 2023-02-28 OliX Pharmaceuticals. Inc. Long double-stranded RNA for RNA interference

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3372684B1 (fr) 2010-08-24 2020-10-07 Sirna Therapeutics, Inc. Agents d'arni à un seul brin contenant un espaceur interne d'acide non nucléique
WO2015051044A2 (fr) * 2013-10-04 2015-04-09 Novartis Ag Formats inédits pour composés organiques utiisables en interférence arn
JP6546161B2 (ja) * 2013-10-04 2019-07-17 ノバルティス アーゲー Ｂ型肝炎ウイルスを治療するための有機化合物
KR102298475B1 (ko) 2013-10-04 2021-09-06 노파르티스 아게 ＲＮＡ 간섭에 사용하기 위한 ＲＮＡｉ 작용제를 위한 3' 말단 캡
EP3052627B1 (fr) * 2013-10-04 2018-08-22 Novartis AG Formats inédits pour composés organiques utilisables en interférence arn

Citations (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4415732A (en) * 1981-03-27 1983-11-15 University Patents, Inc. Phosphoramidite compounds and processes
US4458066A (en) * 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4682195A (en) * 1985-09-30 1987-07-21 General Electric Company Insulated gate device with configured emitter contact pad
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4786600A (en) * 1984-05-25 1988-11-22 The Trustees Of Columbia University In The City Of New York Autocatalytic replication of recombinant RNA
US4828979A (en) * 1984-11-08 1989-05-09 Life Technologies, Inc. Nucleotide analogs for nucleic acid labeling and detection
US4849513A (en) * 1983-12-20 1989-07-18 California Institute Of Technology Deoxyribonucleoside phosphoramidites in which an aliphatic amino group is attached to the sugar ring and their use for the preparation of oligonucleotides containing aliphatic amino groups
US4910300A (en) * 1985-12-11 1990-03-20 Chiron Corporation Method for making nucleic acid probes
US4952496A (en) * 1984-03-30 1990-08-28 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
US5026645A (en) * 1986-10-21 1991-06-25 Takara Shuzo Co., Ltd. RNA polymerase gene, microorganism having said gene and the production of RNA polymerase by the use of said microorganism
US5037735A (en) * 1988-06-24 1991-08-06 Microgenics Corporation Visual discrimination qualitative enzyme complementation assay
US5102802A (en) * 1986-04-01 1992-04-07 University Of Medicine And Dentistry Of New Jersey Gene coding for a protein having T3 polymerase activity
US5573913A (en) * 1994-02-28 1996-11-12 Boehringer Mannheim Gmbh 3'-RNA labelling with terminal transferase
US5591601A (en) * 1993-05-14 1997-01-07 Ohio University Edison Animal Biotechnology Institute DNA polymerase gene expression system utilizing an RNA polymerase co-delivered with the gene expression vector system
USRE35443E (en) * 1989-06-09 1997-02-04 Amoco Corporation Purification of Q Beta replicase
US5643768A (en) * 1989-10-05 1997-07-01 Optein, Inc. Cell-free synthesis and isolation of novel genes and polypeptides
US5645897A (en) * 1992-02-15 1997-07-08 Andra; Jurgen Process and device for surface-modification by physico-chemical reactions of gases or vapors on surfaces, using highly-charged ions
US5705629A (en) * 1995-10-20 1998-01-06 Hybridon, Inc. Methods for H-phosphonate synthesis of mono- and oligonucleotides
US5728525A (en) * 1992-02-12 1998-03-17 Chromagen, Inc. Fluorescent universal nucleic acid end label
US5734039A (en) * 1994-09-15 1998-03-31 Thomas Jefferson University Antisense oligonucleotides targeting cooperating oncogenes
US5776905A (en) * 1996-08-08 1998-07-07 The Board Of Trustees Of The Leland Stamford Junior University Apoptotic regression of intimal vascular lesions
US5795715A (en) * 1991-12-18 1998-08-18 Cis Bio International Process for preparing double-stranded RNA, and its applications
US5824528A (en) * 1992-05-01 1998-10-20 Associated Universities, Inc. Cloning and expression of autogenes encoding RNA poly,erases of T7-like bacteriophages
US5869320A (en) * 1984-03-30 1999-02-09 Brookhaven Science Associates Llc Cloning and expression of the gene for bacteriophage T7 RNA polymerase
US5889136A (en) * 1995-06-09 1999-03-30 The Regents Of The University Of Colorado Orthoester protecting groups in RNA synthesis
US5891681A (en) * 1993-12-22 1999-04-06 Bio Merieux Modified promoter for RNA polymerase, its preparation and its applications
US5898031A (en) * 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US6083482A (en) * 1999-05-11 2000-07-04 Icn Pharmaceuticals, Inc. Conformationally locked nucleosides and oligonucleotides
US6114152A (en) * 1997-12-12 2000-09-05 The Regents Of The University Of California Methods for making nucleic acids
US6262252B1 (en) * 1997-05-19 2001-07-17 Mirus, Inc. Single-step method for labeling nucleic acids with mustard or aziridine labeling reagents
US6268490B1 (en) * 1997-03-07 2001-07-31 Takeshi Imanishi Bicyclonucleoside and oligonucleotide analogues
US6372433B1 (en) * 2000-04-28 2002-04-16 Isis Pharmaceuticals, Inc. Antisense modulation of inhibitor of DNA binding-1 expression
US6376179B1 (en) * 1998-06-17 2002-04-23 Bio Merieux Process for labeling a ribonucleic acid, and labeled RNA fragments which are obtained thereby
US20020086356A1 (en) * 2000-03-30 2002-07-04 Whitehead Institute For Biomedical Research RNA sequence-specific mediators of RNA interference
US20020162126A1 (en) * 2000-03-16 2002-10-31 David Beach Methods and compositions for RNA interference
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US6525191B1 (en) * 1999-05-11 2003-02-25 Kanda S. Ramasamy Conformationally constrained L-nucleosides
US20030077609A1 (en) * 2001-03-25 2003-04-24 Jakobsen Mogens Havsteen Modified oligonucleotides and uses thereof
US20030092905A1 (en) * 1999-03-24 2003-05-15 Exiqon A/S Synthesis of [2.2.1]bicyclo nucleosides
US6573099B2 (en) * 1998-03-20 2003-06-03 Benitec Australia, Ltd. Genetic constructs for delaying or repressing the expression of a target gene
US20030119104A1 (en) * 2001-05-30 2003-06-26 Edward Perkins Chromosome-based platforms
US20030166282A1 (en) * 2002-02-01 2003-09-04 David Brown High potency siRNAS for reducing the expression of target genes
US6639059B1 (en) * 1999-03-24 2003-10-28 Exiqon A/S Synthesis of [2.2.1]bicyclo nucleosides
US6673611B2 (en) * 1998-04-20 2004-01-06 Sirna Therapeutics, Inc. Nucleic acid molecules with novel chemical compositions capable of modulating gene expression
US20040014108A1 (en) * 2002-05-24 2004-01-22 Eldrup Anne B. Oligonucleotides having modified nucleoside units
US20040033602A1 (en) * 2002-06-12 2004-02-19 Ambion, Inc. Methods and compositions relating to polypeptides with RNase III domains that mediate RNA interference
US20040038921A1 (en) * 2001-10-26 2004-02-26 Ribopharma Ag Composition and method for inhibiting expression of a target gene
US20040053875A1 (en) * 1999-01-30 2004-03-18 Ribopharma Ag Method and medicament for inhibiting the expression of a given gene
US20040067882A1 (en) * 2001-10-22 2004-04-08 Alsobrook John P. Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US20040091926A1 (en) * 2002-10-24 2004-05-13 Wyeth Compositions, organisms and methodologies employing a novel human protein phosphatase
US20040147022A1 (en) * 1996-06-06 2004-07-29 Baker Brenda F. 2'-methoxy substituted oligomeric compounds and compositions for use in gene modulations
US6770748B2 (en) * 1997-03-07 2004-08-03 Takeshi Imanishi Bicyclonucleoside and oligonucleotide analogue
US20040171031A1 (en) * 1996-06-06 2004-09-02 Baker Brenda F. Sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
US20040171570A1 (en) * 2002-11-05 2004-09-02 Charles Allerson Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
US20040175703A1 (en) * 1999-11-24 2004-09-09 Ribopharma Ag Compositions and methods for inhibiting expression of a target gene
US6794499B2 (en) * 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
US20040198640A1 (en) * 2003-04-02 2004-10-07 Dharmacon, Inc. Stabilized polynucleotides for use in RNA interference
US20040203024A1 (en) * 1996-06-06 2004-10-14 Baker Brenda F. Modified oligonucleotides for use in RNA interference
US20040203145A1 (en) * 2002-08-07 2004-10-14 University Of Massachusetts Compositions for RNA interference and methods of use thereof
US20040219565A1 (en) * 2002-10-21 2004-11-04 Sakari Kauppinen Oligonucleotides useful for detecting and analyzing nucleic acids of interest
US20040229266A1 (en) * 2000-12-01 2004-11-18 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. RNA interference mediating small RNA molecules
US20050020525A1 (en) * 2002-02-20 2005-01-27 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US20050020521A1 (en) * 2002-09-25 2005-01-27 University Of Massachusetts In vivo gene silencing by chemically modified and stable siRNA
US6849726B2 (en) * 1993-09-02 2005-02-01 Sirna Therapeutics, Inc. Non-nucleotide containing RNA
US20050026160A1 (en) * 2002-11-05 2005-02-03 Charles Allerson Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
US20050058982A1 (en) * 2002-07-26 2005-03-17 Chiron Corporation Modified small interfering RNA molecules and methods of use
US20050080246A1 (en) * 2002-11-05 2005-04-14 Charles Allerson Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
US20050119214A1 (en) * 2003-04-17 2005-06-02 Muthiah Manoharan Nuclease resistant double-stranded ribonucleic acid
US20050214823A1 (en) * 2004-01-13 2005-09-29 Affymetrix, Inc. Methods of analysis of alternative splicing in mouse
US20050223427A1 (en) * 2004-04-01 2005-10-06 Dharmacon, Inc. Modified polynucleotides for reducing off-target effects in RNA interference
US20050244858A1 (en) * 2004-03-15 2005-11-03 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
US7022828B2 (en) * 2001-04-05 2006-04-04 Sirna Theraputics, Inc. siRNA treatment of diseases or conditions related to levels of IKK-gamma
US7053207B2 (en) * 1999-05-04 2006-05-30 Exiqon A/S L-ribo-LNA analogues
US7060809B2 (en) * 2001-09-04 2006-06-13 Exiqon A/S LNA compositions and uses thereof
US20060134787A1 (en) * 2004-12-22 2006-06-22 University Of Massachusetts Methods and compositions for enhancing the efficacy and specificity of single and double blunt-ended siRNA
US20060166910A1 (en) * 2002-07-10 2006-07-27 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. Rna-interference by single-stranded rna molecules
US7084125B2 (en) * 1999-03-18 2006-08-01 Exiqon A/S Xylo-LNA analogues
US20060217336A1 (en) * 2002-02-20 2006-09-28 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US20070029275A1 (en) * 2002-06-13 2007-02-08 Hantman Ken S Multiple chamber container
US20070031843A1 (en) * 2004-04-02 2007-02-08 Rosetta Genomics Bioinformatically detectable group of novel regulatory bacterial and bacterial associated oligonucleotides and uses thereof
US7176304B2 (en) * 2002-02-20 2007-02-13 Mcswiggen James RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20070111228A1 (en) * 2002-12-27 2007-05-17 Amgen Inc. RNA interference

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5241060A (en) * 1982-06-23 1993-08-31 Enzo Diagnostics, Inc. Base moiety-labeled detectable nucleatide
EP0178863A1 (fr) 1984-10-15 1986-04-23 Schering Corporation Systèmes d'expression utilisant des promoteurs de bactériophage T7 et des séquences de gènes
GB8613481D0 (en) * 1986-06-04 1986-07-09 Diatech Ltd Translation of mrna
EP0266032A1 (fr) 1986-08-29 1988-05-04 Beecham Group Plc Enzyme fibrinolytique modifiée
US5998135A (en) 1989-02-24 1999-12-07 Enzo Diagnostics, Inc. Energy transfer hybridization assay using intercalators and lanthanide metals
US6005087A (en) 1995-06-06 1999-12-21 Isis Pharmaceuticals, Inc. 2'-modified oligonucleotides
US5624803A (en) * 1993-10-14 1997-04-29 The Regents Of The University Of California In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom
US5998203A (en) 1996-04-16 1999-12-07 Ribozyme Pharmaceuticals, Inc. Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
US20030044941A1 (en) * 1996-06-06 2003-03-06 Crooke Stanley T. Human RNase III and compositions and uses thereof
US7572582B2 (en) 1997-09-12 2009-08-11 Exiqon A/S Oligonucleotide analogues
WO2003070918A2 (fr) * 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated Inhibition mediee par interference arn d'une expression genique faisant appel a des acides nucleiques interferants courts chimiquement modifies (sina)
US20020173478A1 (en) 2000-11-14 2002-11-21 The Trustees Of The University Of Pennsylvania Post-transcriptional gene silencing by RNAi in mammalian cells
WO2002073504A1 (fr) 2001-03-14 2002-09-19 Gene Logic, Inc. Systeme et procede d'extraction et d'utilisation de donnees d'expression genique provenant de multiples sources
US7074558B2 (en) * 2001-06-07 2006-07-11 Pbi Technology, Inc. Nucleic acid amplification using an RNA polymerase and DNA/RNA mixed polymer intermediate products
US7125664B2 (en) * 2001-06-20 2006-10-24 Dahlia Minc-Golomb Method for identifying genes that are upstream regulators of other genes of interest
CA2454183C (fr) * 2001-07-23 2016-09-06 The Board Of Trustees Of The Leland Stanford Junior University Methodes et compositions pour l'inhibition induite par l'arni de l'expression genetique chez des mammiferes
US6455292B1 (en) * 2001-08-16 2002-09-24 Origene Technologies, Inc Full-length serine protein kinase in brain and pancreas
US7659391B2 (en) 2001-11-05 2010-02-09 Janssen Pharmaceutica N.V. Method for the in vitro synthesis of short double stranded RNAs
US20030203868A1 (en) * 2002-02-06 2003-10-30 Bushman Frederic D. Inhibition of pathogen replication by RNA interference
US7820632B2 (en) * 2002-02-14 2010-10-26 City Of Hope Methods for producing interfering RNA molecules in mammalian cells and therapeutic uses for such molecules
WO2003093430A2 (fr) 2002-05-03 2003-11-13 The Board Of Trustees Of The Leland Stanford Junior University Procedes et compositions a utiliser dans la preparation d'arnsi
US20040248094A1 (en) 2002-06-12 2004-12-09 Ford Lance P. Methods and compositions relating to labeled RNA molecules that reduce gene expression
US20040029275A1 (en) * 2002-08-10 2004-02-12 David Brown Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs
US7923547B2 (en) 2002-09-05 2011-04-12 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
WO2006006948A2 (fr) * 2002-11-14 2006-01-19 Dharmacon, Inc. Methodes et compositions permettant de selectionner des arnsi presentant une fonctionnalite amelioree
US20050256071A1 (en) 2003-07-15 2005-11-17 California Institute Of Technology Inhibitor nucleic acids
JP4486928B2 (ja) * 2003-10-09 2010-06-23 タカラバイオ株式会社 ヒトＦｌｔ３の機能を抑制するための組成物
US7790878B2 (en) * 2004-10-22 2010-09-07 Alnylam Pharmaceuticals, Inc. RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof
US20060142228A1 (en) * 2004-12-23 2006-06-29 Ambion, Inc. Methods and compositions concerning siRNA's as mediators of RNA interference

Patent Citations (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) * 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4415732A (en) * 1981-03-27 1983-11-15 University Patents, Inc. Phosphoramidite compounds and processes
US4849513A (en) * 1983-12-20 1989-07-18 California Institute Of Technology Deoxyribonucleoside phosphoramidites in which an aliphatic amino group is attached to the sugar ring and their use for the preparation of oligonucleotides containing aliphatic amino groups
US5869320A (en) * 1984-03-30 1999-02-09 Brookhaven Science Associates Llc Cloning and expression of the gene for bacteriophage T7 RNA polymerase
US4952496A (en) * 1984-03-30 1990-08-28 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
US4786600A (en) * 1984-05-25 1988-11-22 The Trustees Of Columbia University In The City Of New York Autocatalytic replication of recombinant RNA
US4828979A (en) * 1984-11-08 1989-05-09 Life Technologies, Inc. Nucleotide analogs for nucleic acid labeling and detection
US4683202B1 (fr) * 1985-03-28 1990-11-27 Cetus Corp
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4682195A (en) * 1985-09-30 1987-07-21 General Electric Company Insulated gate device with configured emitter contact pad
US4910300A (en) * 1985-12-11 1990-03-20 Chiron Corporation Method for making nucleic acid probes
US5102802A (en) * 1986-04-01 1992-04-07 University Of Medicine And Dentistry Of New Jersey Gene coding for a protein having T3 polymerase activity
US5026645A (en) * 1986-10-21 1991-06-25 Takara Shuzo Co., Ltd. RNA polymerase gene, microorganism having said gene and the production of RNA polymerase by the use of said microorganism
US5037735A (en) * 1988-06-24 1991-08-06 Microgenics Corporation Visual discrimination qualitative enzyme complementation assay
USRE35443E (en) * 1989-06-09 1997-02-04 Amoco Corporation Purification of Q Beta replicase
US5643768A (en) * 1989-10-05 1997-07-01 Optein, Inc. Cell-free synthesis and isolation of novel genes and polypeptides
US5795715A (en) * 1991-12-18 1998-08-18 Cis Bio International Process for preparing double-stranded RNA, and its applications
US5728525A (en) * 1992-02-12 1998-03-17 Chromagen, Inc. Fluorescent universal nucleic acid end label
US5645897A (en) * 1992-02-15 1997-07-08 Andra; Jurgen Process and device for surface-modification by physico-chemical reactions of gases or vapors on surfaces, using highly-charged ions
US5824528A (en) * 1992-05-01 1998-10-20 Associated Universities, Inc. Cloning and expression of autogenes encoding RNA poly,erases of T7-like bacteriophages
US5591601A (en) * 1993-05-14 1997-01-07 Ohio University Edison Animal Biotechnology Institute DNA polymerase gene expression system utilizing an RNA polymerase co-delivered with the gene expression vector system
US6849726B2 (en) * 1993-09-02 2005-02-01 Sirna Therapeutics, Inc. Non-nucleotide containing RNA
US5891681A (en) * 1993-12-22 1999-04-06 Bio Merieux Modified promoter for RNA polymerase, its preparation and its applications
US5573913A (en) * 1994-02-28 1996-11-12 Boehringer Mannheim Gmbh 3'-RNA labelling with terminal transferase
US5734039A (en) * 1994-09-15 1998-03-31 Thomas Jefferson University Antisense oligonucleotides targeting cooperating oncogenes
US5889136A (en) * 1995-06-09 1999-03-30 The Regents Of The University Of Colorado Orthoester protecting groups in RNA synthesis
US5705629A (en) * 1995-10-20 1998-01-06 Hybridon, Inc. Methods for H-phosphonate synthesis of mono- and oligonucleotides
US20040203024A1 (en) * 1996-06-06 2004-10-14 Baker Brenda F. Modified oligonucleotides for use in RNA interference
US5898031A (en) * 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US6107094A (en) * 1996-06-06 2000-08-22 Isis Pharmaceuticals, Inc. Oligoribonucleotides and ribonucleases for cleaving RNA
US20040147022A1 (en) * 1996-06-06 2004-07-29 Baker Brenda F. 2'-methoxy substituted oligomeric compounds and compositions for use in gene modulations
US20040171031A1 (en) * 1996-06-06 2004-09-02 Baker Brenda F. Sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
US20040171033A1 (en) * 1996-06-06 2004-09-02 Baker Brenda F. 2'-substituted oligomeric compounds and compositions for use in gene modulations
US5776905A (en) * 1996-08-08 1998-07-07 The Board Of Trustees Of The Leland Stamford Junior University Apoptotic regression of intimal vascular lesions
US6268490B1 (en) * 1997-03-07 2001-07-31 Takeshi Imanishi Bicyclonucleoside and oligonucleotide analogues
US6770748B2 (en) * 1997-03-07 2004-08-03 Takeshi Imanishi Bicyclonucleoside and oligonucleotide analogue
US6262252B1 (en) * 1997-05-19 2001-07-17 Mirus, Inc. Single-step method for labeling nucleic acids with mustard or aziridine labeling reagents
US6794499B2 (en) * 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
US7034133B2 (en) * 1997-09-12 2006-04-25 Exiqon A/S Oligonucleotide analogues
US6114152A (en) * 1997-12-12 2000-09-05 The Regents Of The University Of California Methods for making nucleic acids
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US6573099B2 (en) * 1998-03-20 2003-06-03 Benitec Australia, Ltd. Genetic constructs for delaying or repressing the expression of a target gene
US6673611B2 (en) * 1998-04-20 2004-01-06 Sirna Therapeutics, Inc. Nucleic acid molecules with novel chemical compositions capable of modulating gene expression
US20050176018A1 (en) * 1998-04-20 2005-08-11 Sirna Therapeutics, Inc. Chemically modified double stranded nucleic acid molecules
US6376179B1 (en) * 1998-06-17 2002-04-23 Bio Merieux Process for labeling a ribonucleic acid, and labeled RNA fragments which are obtained thereby
US20050100907A1 (en) * 1999-01-30 2005-05-12 Ribopharma, Ag Method and medicament for inhibiting the expression of a given gene
US20040053875A1 (en) * 1999-01-30 2004-03-18 Ribopharma Ag Method and medicament for inhibiting the expression of a given gene
US20040072779A1 (en) * 1999-01-30 2004-04-15 Ribopharma Ag Method and medicament for inhibiting the expression of a given gene
US20040102408A1 (en) * 1999-01-30 2004-05-27 Ribopharma Ag Method and medicament for inhibiting the expression of a given gene
US7084125B2 (en) * 1999-03-18 2006-08-01 Exiqon A/S Xylo-LNA analogues
US6639059B1 (en) * 1999-03-24 2003-10-28 Exiqon A/S Synthesis of [2.2.1]bicyclo nucleosides
US20030092905A1 (en) * 1999-03-24 2003-05-15 Exiqon A/S Synthesis of [2.2.1]bicyclo nucleosides
US6734291B2 (en) * 1999-03-24 2004-05-11 Exiqon A/S Synthesis of [2.2.1]bicyclo nucleosides
US7053207B2 (en) * 1999-05-04 2006-05-30 Exiqon A/S L-ribo-LNA analogues
US6083482A (en) * 1999-05-11 2000-07-04 Icn Pharmaceuticals, Inc. Conformationally locked nucleosides and oligonucleotides
US6525191B1 (en) * 1999-05-11 2003-02-25 Kanda S. Ramasamy Conformationally constrained L-nucleosides
US20040175703A1 (en) * 1999-11-24 2004-09-09 Ribopharma Ag Compositions and methods for inhibiting expression of a target gene
US20020162126A1 (en) * 2000-03-16 2002-10-31 David Beach Methods and compositions for RNA interference
US20030108923A1 (en) * 2000-03-30 2003-06-12 Whitehead Institute For Biomedical Research RNA sequence-specific mediators of RNA interference
US20020086356A1 (en) * 2000-03-30 2002-07-04 Whitehead Institute For Biomedical Research RNA sequence-specific mediators of RNA interference
US6372433B1 (en) * 2000-04-28 2002-04-16 Isis Pharmaceuticals, Inc. Antisense modulation of inhibitor of DNA binding-1 expression
US7056704B2 (en) * 2000-12-01 2006-06-06 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. RNA interference mediating small RNA molecules
US20040229266A1 (en) * 2000-12-01 2004-11-18 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. RNA interference mediating small RNA molecules
US7078196B2 (en) * 2000-12-01 2006-07-18 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften, E.V. RNA interference mediating small RNA molecules
US20030077609A1 (en) * 2001-03-25 2003-04-24 Jakobsen Mogens Havsteen Modified oligonucleotides and uses thereof
US7022828B2 (en) * 2001-04-05 2006-04-04 Sirna Theraputics, Inc. siRNA treatment of diseases or conditions related to levels of IKK-gamma
US20030119104A1 (en) * 2001-05-30 2003-06-26 Edward Perkins Chromosome-based platforms
US7060809B2 (en) * 2001-09-04 2006-06-13 Exiqon A/S LNA compositions and uses thereof
US20040067882A1 (en) * 2001-10-22 2004-04-08 Alsobrook John P. Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US20040038921A1 (en) * 2001-10-26 2004-02-26 Ribopharma Ag Composition and method for inhibiting expression of a target gene
US20030166282A1 (en) * 2002-02-01 2003-09-04 David Brown High potency siRNAS for reducing the expression of target genes
US20060217335A1 (en) * 2002-02-20 2006-09-28 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US20070004665A1 (en) * 2002-02-20 2007-01-04 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US20050020525A1 (en) * 2002-02-20 2005-01-27 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US20060217334A1 (en) * 2002-02-20 2006-09-28 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US7176304B2 (en) * 2002-02-20 2007-02-13 Mcswiggen James RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20070004663A1 (en) * 2002-02-20 2007-01-04 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US20060217337A1 (en) * 2002-02-20 2006-09-28 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US20060217336A1 (en) * 2002-02-20 2006-09-28 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US20070004667A1 (en) * 2002-02-20 2007-01-04 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US20040014108A1 (en) * 2002-05-24 2004-01-22 Eldrup Anne B. Oligonucleotides having modified nucleoside units
US20040033602A1 (en) * 2002-06-12 2004-02-19 Ambion, Inc. Methods and compositions relating to polypeptides with RNase III domains that mediate RNA interference
US20070029275A1 (en) * 2002-06-13 2007-02-08 Hantman Ken S Multiple chamber container
US20060166910A1 (en) * 2002-07-10 2006-07-27 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. Rna-interference by single-stranded rna molecules
US20050058982A1 (en) * 2002-07-26 2005-03-17 Chiron Corporation Modified small interfering RNA molecules and methods of use
US20040203145A1 (en) * 2002-08-07 2004-10-14 University Of Massachusetts Compositions for RNA interference and methods of use thereof
US20050020521A1 (en) * 2002-09-25 2005-01-27 University Of Massachusetts In vivo gene silencing by chemically modified and stable siRNA
US20040219565A1 (en) * 2002-10-21 2004-11-04 Sakari Kauppinen Oligonucleotides useful for detecting and analyzing nucleic acids of interest
US20040091926A1 (en) * 2002-10-24 2004-05-13 Wyeth Compositions, organisms and methodologies employing a novel human protein phosphatase
US20050080246A1 (en) * 2002-11-05 2005-04-14 Charles Allerson Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
US20050026160A1 (en) * 2002-11-05 2005-02-03 Charles Allerson Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
US20040171570A1 (en) * 2002-11-05 2004-09-02 Charles Allerson Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
US20070111228A1 (en) * 2002-12-27 2007-05-17 Amgen Inc. RNA interference
US20040198640A1 (en) * 2003-04-02 2004-10-07 Dharmacon, Inc. Stabilized polynucleotides for use in RNA interference
US20050119214A1 (en) * 2003-04-17 2005-06-02 Muthiah Manoharan Nuclease resistant double-stranded ribonucleic acid
US20050214823A1 (en) * 2004-01-13 2005-09-29 Affymetrix, Inc. Methods of analysis of alternative splicing in mouse
US20050244858A1 (en) * 2004-03-15 2005-11-03 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
US20050223427A1 (en) * 2004-04-01 2005-10-06 Dharmacon, Inc. Modified polynucleotides for reducing off-target effects in RNA interference
US20070031843A1 (en) * 2004-04-02 2007-02-08 Rosetta Genomics Bioinformatically detectable group of novel regulatory bacterial and bacterial associated oligonucleotides and uses thereof
US20060134787A1 (en) * 2004-12-22 2006-06-22 University Of Massachusetts Methods and compositions for enhancing the efficacy and specificity of single and double blunt-ended siRNA

Cited By (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8524680B2 (en) 2002-02-01 2013-09-03 Applied Biosystems, Llc High potency siRNAS for reducing the expression of target genes
US10106793B2 (en) 2002-02-01 2018-10-23 Life Technologies Corporation Double-stranded oligonucleotides
US20030166282A1 (en) * 2002-02-01 2003-09-04 David Brown High potency siRNAS for reducing the expression of target genes
US10626398B2 (en) 2002-02-01 2020-04-21 Life Technologies Corporation Oligonucleotide compositions with enhanced efficiency
US9592250B2 (en) 2002-02-01 2017-03-14 Life Technologies Corporation Double-stranded oligonucleotides
US9777275B2 (en) 2002-02-01 2017-10-03 Life Technologies Corporation Oligonucleotide compositions with enhanced efficiency
US9796978B1 (en) 2002-02-01 2017-10-24 Life Technologies Corporation Oligonucleotide compositions with enhanced efficiency
US10196640B1 (en) 2002-02-01 2019-02-05 Life Technologies Corporation Oligonucleotide compositions with enhanced efficiency
US10036025B2 (en) 2002-02-01 2018-07-31 Life Technologies Corporation Oligonucleotide compositions with enhanced efficiency
US8815821B2 (en) 2002-02-01 2014-08-26 Life Technologies Corporation Double-stranded oligonucleotides
US20100075423A1 (en) * 2002-06-12 2010-03-25 Life Technologies Corporation Methods and compositions relating to polypeptides with rnase iii domains that mediate rna interference
US20040033602A1 (en) * 2002-06-12 2004-02-19 Ambion, Inc. Methods and compositions relating to polypeptides with RNase III domains that mediate RNA interference
US20040248094A1 (en) * 2002-06-12 2004-12-09 Ford Lance P. Methods and compositions relating to labeled RNA molecules that reduce gene expression
US8426380B2 (en) 2004-09-10 2013-04-23 Somagenics, Inc. Inhibition of viral gene expression using small interfering RNA
US8058255B2 (en) 2004-12-23 2011-11-15 Applied Biosystems, Llc Methods and compositions concerning siRNA's as mediators of RNA interference
US20100159591A1 (en) * 2004-12-23 2010-06-24 Life Technologies Corporation METHODS AND COMPOSITIONS CONCERNING siRNA'S AS MEDIATORS OF RNA INTERFERENCE
US8481506B2 (en) 2006-12-05 2013-07-09 Rosetta Genomics, Ltd. Nucleic acids involved in viral infection
US20100184205A1 (en) * 2006-12-05 2010-07-22 Issac Bentwich Nucleic acids involved in viral infection
WO2009024834A2 (fr) * 2006-12-05 2009-02-26 Rosetta Genomics Ltd Acides nucléiques impliques dans les infections virales
WO2009024834A3 (fr) * 2006-12-05 2011-12-29 Rosetta Genomics Ltd Acides nucléiques impliques dans les infections virales
US8586726B2 (en) 2007-07-18 2013-11-19 The Trustees Of Columbia University In The City Of New York Tissue-specific MicroRNAs and compositions and uses thereof
US20100197772A1 (en) * 2007-07-18 2010-08-05 Andrea Califano Tissue-Specific MicroRNAs and Compositions and Uses Thereof
CN101835789B (zh) * 2007-08-27 2015-06-24 北京强新生物科技有限公司 不对称干扰rna的组合物及其用途
US9328345B2 (en) 2007-08-27 2016-05-03 1 Globe Health Institute Llc Compositions of asymmetric interfering RNA and uses thereof
US20100286378A1 (en) * 2007-08-27 2010-11-11 Boston Biomedical, Inc. Composition of Asymmetric RNA Duplex As MicroRNA Mimetic or Inhibitor
CN101835789A (zh) * 2007-08-27 2010-09-15 波士顿生物医药公司 不对称干扰rna的组合物及其用途
US10266821B2 (en) 2007-08-27 2019-04-23 1Globe Health Institute Llc Compositions of asymmetric interfering RNA and uses thereof
US10927376B2 (en) 2007-08-27 2021-02-23 1Globe Health Institute Llc Compositions of asymmetric interfering RNA and uses thereof
US20090208564A1 (en) * 2007-08-27 2009-08-20 Chiang Jia Li Compositions of asymmetric interfering RNA and uses thereof
WO2009029688A3 (fr) * 2007-08-27 2009-07-02 Boston Biomedical Inc Compositions d'arn interférent asymétrique et leurs utilisations
EP2222848A4 (fr) * 2007-12-18 2011-06-22 Lee Dong Ki Nouvelle structure de petit arn interférent permettant d'atténuer les effets hors cible et d'alléger la saturation de mécanisme d'arn interférent, et utilisation
EP2222848A2 (fr) * 2007-12-18 2010-09-01 Lee, Dong Ki Nouvelle structure de petit arn interférent permettant d'atténuer les effets hors cible et d'alléger la saturation de mécanisme d'arn interférent, et utilisation
AU2008339215B2 (en) * 2007-12-18 2013-05-23 Dong Ki Lee Novel siRNA structure for minimizing off-target effects and relaxing saturation of RNAi machinery and the use thereof
US20100018849A1 (en) * 2008-07-25 2010-01-28 Air Products And Chemicals, Inc. Removal of Trace Arsenic Impurities from Triethylphosphate (TEPO)
US9938530B2 (en) 2008-09-22 2018-04-10 Rxi Pharmaceuticals Corporation RNA interference in skin indications
US10041073B2 (en) 2008-09-22 2018-08-07 Rxi Pharmaceuticals Corporation Reduced size self-delivering RNAi compounds
US11396654B2 (en) 2008-09-22 2022-07-26 Phio Pharmaceuticals Corp. Neutral nanotransporters
US10876119B2 (en) 2008-09-22 2020-12-29 Phio Pharmaceuticals Corp. Reduced size self-delivering RNAI compounds
US9175289B2 (en) 2008-09-22 2015-11-03 Rxi Pharmaceuticals Corporation Reduced size self-delivering RNAi compounds
US10815485B2 (en) 2008-09-22 2020-10-27 Phio Pharmaceuticals Corp. RNA interference in skin indications
US10774330B2 (en) 2008-09-22 2020-09-15 Phio Pharmaceuticals Corp. Reduced size self-delivering RNAI compounds
US20110237648A1 (en) * 2008-09-22 2011-09-29 Rxi Pharmaceuticals Corporation Rna interference in skin indications
US8664189B2 (en) 2008-09-22 2014-03-04 Rxi Pharmaceuticals Corporation RNA interference in skin indications
US10138485B2 (en) 2008-09-22 2018-11-27 Rxi Pharmaceuticals Corporation Neutral nanotransporters
US9303259B2 (en) 2008-09-22 2016-04-05 Rxi Pharmaceuticals Corporation RNA interference in skin indications
US8796443B2 (en) 2008-09-22 2014-08-05 Rxi Pharmaceuticals Corporation Reduced size self-delivering RNAi compounds
US8779115B2 (en) 2008-10-15 2014-07-15 Somagenics Inc. Short hairpin RNAs for inhibition of gene expression
US20100112686A1 (en) * 2008-10-15 2010-05-06 Qing Ge Short hairpin rnas for inhibition of gene expression
US8283460B2 (en) * 2008-10-15 2012-10-09 Somagenics, Inc. Short hairpin RNAs for inhibition of gene expression
US10167471B2 (en) 2009-01-05 2019-01-01 Rxi Pharmaceuticals Corporation Inhibition of PCSK9 through RNAI
US9493774B2 (en) 2009-01-05 2016-11-15 Rxi Pharmaceuticals Corporation Inhibition of PCSK9 through RNAi
US11667915B2 (en) 2009-02-04 2023-06-06 Phio Pharmaceuticals Corp. RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
US9745574B2 (en) 2009-02-04 2017-08-29 Rxi Pharmaceuticals Corporation RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
US10479992B2 (en) 2009-02-04 2019-11-19 Phio Pharmaceuticals Corp. RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
US8871730B2 (en) 2009-07-13 2014-10-28 Somagenics Inc. Chemical modification of short small hairpin RNAs for inhibition of gene expression
US9816091B2 (en) 2009-07-13 2017-11-14 Somagenics, Inc. Chemical modification of short small hairpin RNAs for inhibition of gene expression
US10870850B2 (en) 2009-07-13 2020-12-22 Somagenics, Inc. Chemical modification of short small hairpin RNAs for inhibition of gene expression
US9095504B2 (en) 2010-03-24 2015-08-04 Rxi Pharmaceuticals Corporation RNA interference in ocular indications
US10913948B2 (en) 2010-03-24 2021-02-09 Phio Pharmaceuticals Corp. RNA interference in dermal and fibrotic indications
US9080171B2 (en) 2010-03-24 2015-07-14 RXi Parmaceuticals Corporation Reduced size self-delivering RNAi compounds
US10662430B2 (en) 2010-03-24 2020-05-26 Phio Pharmaceuticals Corp. RNA interference in ocular indications
US11118178B2 (en) 2010-03-24 2021-09-14 Phio Pharmaceuticals Corp. Reduced size self-delivering RNAI compounds
US11584933B2 (en) 2010-03-24 2023-02-21 Phio Pharmaceuticals Corp. RNA interference in ocular indications
US10240149B2 (en) 2010-03-24 2019-03-26 Phio Pharmaceuticals Corp. Reduced size self-delivering RNAi compounds
US9963702B2 (en) 2010-03-24 2018-05-08 Rxi Pharmaceuticals Corporation RNA interference in dermal and fibrotic indications
US9340786B2 (en) 2010-03-24 2016-05-17 Rxi Pharmaceuticals Corporation RNA interference in dermal and fibrotic indications
US10184124B2 (en) 2010-03-24 2019-01-22 Phio Pharmaceuticals Corp. RNA interference in ocular indications
US10214744B2 (en) 2010-10-22 2019-02-26 Sungkyunkwan University Foundation For Corporate Collaboration Nucleic acid molecules inducing RNA interference, and uses thereof
US10829760B2 (en) 2010-10-22 2020-11-10 Olix Pharmaceuticals, Inc. Nucleic acid molecules inducing RNA interference, and uses thereof
US10883105B2 (en) 2012-05-22 2021-01-05 Olix Pharmaceuticals, Inc. RNA-interference-inducing nucleic acid molecule able to penetrate into cells, and use therefor
US10125362B2 (en) 2012-05-22 2018-11-13 Olix Pharmaceuticals, Inc. RNA-interference-inducing nucleic acid molecule able to penetrate into cells, and use therefor
US10934550B2 (en) 2013-12-02 2021-03-02 Phio Pharmaceuticals Corp. Immunotherapy of cancer
US11279934B2 (en) 2014-04-28 2022-03-22 Phio Pharmaceuticals Corp. Methods for treating cancer using nucleic acids targeting MDM2 or MYCN
US10900039B2 (en) 2014-09-05 2021-01-26 Phio Pharmaceuticals Corp. Methods for treating aging and skin disorders using nucleic acids targeting Tyr or MMP1
US11926828B2 (en) 2014-09-05 2024-03-12 Phio Pharmaceuticals Corp. Methods for treating aging and skin disorders using nucleic acids targeting TYR or MMP1
US11001845B2 (en) 2015-07-06 2021-05-11 Phio Pharmaceuticals Corp. Nucleic acid molecules targeting superoxide dismutase 1 (SOD1)
US10808247B2 (en) 2015-07-06 2020-10-20 Phio Pharmaceuticals Corp. Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
US11021707B2 (en) 2015-10-19 2021-06-01 Phio Pharmaceuticals Corp. Reduced size self-delivering nucleic acid compounds targeting long non-coding RNA
US10590423B2 (en) 2015-11-16 2020-03-17 Olix Pharmaceuticals, Inc. Treatment of age-related macular degeneration using RNA complexes that target MyD88 or TLR3
US10947541B2 (en) 2016-02-02 2021-03-16 Olix Pharmaceuticals, Inc. Treatment of atopic dermatitis and asthma using RNA complexes that target IL4Rα, TRPA1, or F2RL1
US10519449B2 (en) 2016-02-02 2019-12-31 Olix Pharmaceuticals, Inc. Treatment of angiogenesis-associated diseases using RNA complexes that target ANGPT2 and PDGFB
US10829761B2 (en) 2016-04-11 2020-11-10 Olix Pharmaceuticals, Inc. Treatment of idiopathic pulmonary fibrosis using RNA complexes that target connective tissue growth factor
US11040057B2 (en) 2016-06-29 2021-06-22 Olix Pharmaceuticals, Inc. Pharmaceutical compositions and methods for potentiating gene silencing
US11591600B2 (en) 2017-02-10 2023-02-28 OliX Pharmaceuticals. Inc. Long double-stranded RNA for RNA interference

Also Published As

Publication number Publication date
EP1830866A2 (fr) 2007-09-12
WO2006078414A2 (fr) 2006-07-27
WO2006078414A3 (fr) 2007-01-25
US20100159591A1 (en) 2010-06-24
US8058255B2 (en) 2011-11-15

Similar Documents

Publication Publication Date Title
US8058255B2 (en) Methods and compositions concerning siRNA's as mediators of RNA interference
US20120122217A1 (en) METHODS AND COMPOSITIONS FOR REDUCING TARGET GENE EXPRESSION USING COCKTAILS OF siRNAS OR CONSTRUCTS EXPRESSING siRNAS
US20130230920A1 (en) Methods and compositions relating to polypeptides with rnase iii domains that mediate rna interference
US8524680B2 (en) High potency siRNAS for reducing the expression of target genes
US10774332B2 (en) Interfering RNA molecules
US11359196B2 (en) Sequence-specific inhibition of small RNA function
US20050186589A1 (en) Interspersed repetitive element RNAs as substrates, inhibitors and delivery vehicles for RNAi
US20100184039A1 (en) Methods and compositions relating to labeled rna molecules that reduce gene expression
US20110159586A1 (en) Compositions and methods for modulating gene expression using asymmetrically-active precursor polynucleotides
JP2004526422A (ja) Ｒｎａ干渉を媒介する短鎖ｒｎａ分子
US20050164212A1 (en) Modulation of gene expression using DNA-RNA hybrids
US20100075423A1 (en) Methods and compositions relating to polypeptides with rnase iii domains that mediate rna interference
Gallozzi et al. Prnp knockdown in transgenic mice using RNA interference
AU2014240287B2 (en) Sequence-specific inhibition of small RNA function
AU2003212886A1 (en) High potency siRNAs for reducing the expression of target genes
Liu Regulatory mechanism of the RNAi pathway

Legal Events

Date Code Title Description
AS Assignment

Owner name: AMBION, INC., TEXAS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FORD, LANCE P.;KREBS, JOSEPH;REEL/FRAME:016436/0252

Effective date: 20050203

AS Assignment

Owner name: APPLERA CORPORATION, CALIFORNIA

Free format text: REDACED AGREEMENT AND PLAN OF MERGER DOCUMENT;ASSIGNOR:AMBION, INC.;REEL/FRAME:019215/0576

Effective date: 20051224

AS Assignment

Owner name: BANK OF AMERICA, N.A, AS COLLATERAL AGENT, WASHING

Free format text: SECURITY AGREEMENT;ASSIGNOR:APPLIED BIOSYSTEMS, LLC;REEL/FRAME:021976/0001

Effective date: 20081121

Owner name: BANK OF AMERICA, N.A, AS COLLATERAL AGENT,WASHINGT

Free format text: SECURITY AGREEMENT;ASSIGNOR:APPLIED BIOSYSTEMS, LLC;REEL/FRAME:021976/0001

Effective date: 20081121

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO PAY ISSUE FEE

AS Assignment

Owner name: APPLIED BIOSYSTEMS INC.,CALIFORNIA

Free format text: CHANGE OF NAME;ASSIGNOR:APPLERA CORPORATION;REEL/FRAME:023994/0538

Effective date: 20080701

Owner name: APPLIED BIOSYSTEMS, LLC,CALIFORNIA

Free format text: MERGER;ASSIGNOR:APPLIED BIOSYSTEMS INC.;REEL/FRAME:023994/0587

Effective date: 20081121

Owner name: APPLIED BIOSYSTEMS INC., CALIFORNIA

Free format text: CHANGE OF NAME;ASSIGNOR:APPLERA CORPORATION;REEL/FRAME:023994/0538

Effective date: 20080701

Owner name: APPLIED BIOSYSTEMS, LLC, CALIFORNIA

Free format text: MERGER;ASSIGNOR:APPLIED BIOSYSTEMS INC.;REEL/FRAME:023994/0587

Effective date: 20081121

AS Assignment

Owner name: APPLIED BIOSYSTEMS, INC., CALIFORNIA

Free format text: LIEN RELEASE;ASSIGNOR:BANK OF AMERICA, N.A.;REEL/FRAME:030182/0677

Effective date: 20100528

AS Assignment

Owner name: APPLIED BIOSYSTEMS, LLC, CALIFORNIA

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY NAME PREVIOUSLY RECORDED AT REEL: 030182 FRAME: 0706. ASSIGNOR(S) HEREBY CONFIRMS THE RELEASE OF SECURITY INTEREST;ASSIGNOR:BANK OF AMERICA, N.A.;REEL/FRAME:038006/0746

Effective date: 20100528

Owner name: APPLIED BIOSYSTEMS, LLC, CALIFORNIA

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY NAME PREVIOUSLY RECORDED AT REEL: 030182 FRAME: 00677. ASSIGNOR(S) HEREBY CONFIRMS THE RELEASE OF SECURITY INTEREST;ASSIGNOR:BANK OF AMERICA, N.A.;REEL/FRAME:038006/0746

Effective date: 20100528